VONVENDI Drug Profile

Summary for Tradename: VONVENDI

High Confidence Patents:	7
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for VONVENDI

Recent Clinical Trials for VONVENDI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of North Carolina	Phase 3
University of Pittsburgh	Phase 3
Duke University	Phase 3

See all VONVENDI clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VONVENDI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VONVENDI Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2037-07-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2039-02-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2039-04-30	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2040-12-22	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2041-08-23	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2034-01-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for VONVENDI Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2037-06-14	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2018-06-19	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2015-11-14	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2022-09-12	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2029-08-21	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2033-03-15	Patent claims search

International Patents for VONVENDI

Country	Patent Number	Estimated Expiration
Hungary	E025236
Japan	6860618
Japan	6694409
Poland	2914291
Australia	2013337638
China	105949314

Supplementary Protection Certificates for VONVENDI

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122023000018	Germany		PRODUCT NAME: SUTIMLIMAB; REGISTRATION NO/DATE: EU/1/22/1687 20221115
C202330017	Spain		PRODUCT NAME: ENJAYMO - SUTIMLIMAB; NATIONAL AUTHORISATION NUMBER: EU/1/22/1687; DATE OF AUTHORISATION: 20221115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1687; DATE OF FIRST AUTHORISATION IN EEA: 20221115
CR 2023 00012	Denmark		PRODUCT NAME: SUTIMLIMAB; REG. NO/DATE: EU/1/22/1687 20221123
PA2023510,C2914291	Lithuania		PRODUCT NAME: SUTIMLIMABAS; REGISTRATION NO/DATE: EU/1/22/1687 20221115
2023C/518	Belgium		PRODUCT NAME: SUTIMLIMAB; AUTHORISATION NUMBER AND DATE: EU/1/22/1687 20221123
301232	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT

Market Dynamics and Financial Trajectory for VONVENDI: A Biologic Breakthrough in Hemophilia A

Last updated: September 29, 2025

Introduction

VONVENDI (von Willebrand Factor [rVWF] - rFVIII concentrate) is a recombinant biologic therapy designed to treat and prevent bleeding episodes in patients with von Willebrand disease (VWD). As a pioneering agent in the biologic landscape, VONVENDI's market dynamics are influenced by evolving clinical profiles, competitive landscape, regulatory pathways, and broader healthcare trends. This analysis examines key factors shaping its market trajectory and financial prospects, providing insights crucial for stakeholders in the pharmaceutical and biotech sectors.

Market Overview and Therapeutic Landscape

Unmet Medical Need in Bleeding Disorders

Von Willebrand disease, affecting approximately 1% of the global population, manifests as a bleeding disorder resulting from deficiency or dysfunction of von Willebrand factor (vWF) and factor VIII (FVIII) [1]. While mild cases often manage bleeding with desmopressin, severe cases require replacement therapies such as plasma-derived or recombinant products.

VONVENDI offers a recombinant alternative with distinct advantages: reduced risk of bloodborne pathogen transmission, consistent supply, and potential for less immunogenicity. Its approval in multiple jurisdictions (FDA, EMA) underscores its clinical significance [2].

Current Market Players and Competition

Market competitors include plasma-derived VWF/FVIII concentrates (e.g., Humate-P, Wilate), other recombinant products like octocog alfa (Afstyla), and emerging gene therapies. The traditional market relies heavily on these therapies, with the global bleeding disorder therapeutics market valued over USD 2.8 billion in 2022, expected to grow at approximately 6% CAGR through 2030 [3].

VONVENDI occupies a niche as a recombinant, non-viral product, attracting patients seeking safer, standardized options. Its differentiation potential hinges on pharmacokinetics, dosing frequency, and immunogenicity profile.

Market Dynamics Influencing VONVENDI's Trajectory

Regulatory Environment

Regulatory acceptance shapes market acceptance. Given VONVENDI's recombinant nature and stringent approval pathways, its positioning is bolstered by favorable safety profiles and evidence of efficacy. Recent approvals in major markets (US, EU) facilitate broader adoption, while evolving regulatory guidance emphasizes real-world evidence and pharmacovigilance—factors likely to influence future market penetration [4].

Pricing and Reimbursement

Pricing strategies impact market uptake. As a premium recombinant biologic, VONVENDI's cost-effectiveness is scrutinized against plasma-derived options. Reimbursement policies, especially in the US and Europe, are increasingly favorable for recombinant therapies, owing to safety and consistency benefits. Insurance coverage and patient access programs are critical to expanding utilization.

Clinical Adoption and Physician Preferences

Physician familiarity, clinical guidelines, and perceived benefits drive adoption. The availability of VONVENDI as a tailored therapy for specific patient populations (e.g., those with inhibitors or severe VWD) influences prescription patterns. Continuous clinician education on its advantages over older therapies enhances acceptance.

Patient-Centric Factors

Patient preference for recombinant therapies due to safety, convenience, and potentially reduced infusion frequency favors VONVENDI. Furthermore, the growing emphasis on personalized medicine aligns with the product's profile, encouraging sustained demand.

Market Penetration Challenges

Barriers include established treatment routines, cost considerations, and competition from biosimilars and emerging therapies such as gene editing and gene therapy approaches, which promise potentially curative outcomes and could disrupt traditional treatment landscapes [5].

Financial Trajectory and Revenue Outlook

Historical Performance

As a relatively new entrant, VONVENDI's revenue generation has been incremental but promising. Initial launch phases indicated strong uptake among high-risk patient subsets, reinforcing its premium positioning.

Projected Growth Patterns

Market analysts project a compound annual growth rate (CAGR) of approximately 7-10% for VONVENDI over the next five years, driven by expanding indications, increased awareness, and geographic expansion, particularly into emerging markets with rising healthcare investments [6].

Revenue Drivers

Key drivers include:

• Increasing prevalence of von Willebrand disease diagnosis and treatment.
• Adoption in acute and prophylactic settings.
• Potential enhancements in formulation for less frequent dosing.
• Strategic partnerships and licensing agreements.

Competitive Risks

Potential threats involve biosimilar entries, innovation in gene therapy (e.g., Parkin et al. 2021), and shifts toward curative approaches, which could reduce demand for replacement therapies. Pricing pressures and reimbursement hurdles in cost-conscious markets may temper revenue growth.

Emerging Trends and Their Impact

Gene Therapy and Curative Approaches

Gene therapy trials targeting VWD and related bleeding disorders are advancing rapidly, with some early-phase therapies showing promising durability and safety profiles [7]. While these therapies currently face regulatory and logistical hurdles, their eventual commercialization could redefine the market landscape, potentially diminishing the long-term role of biologics like VONVENDI.

Personalized Medicine and Diagnostics

Advancements in diagnostics enable tailored therapy; VONVENDI's flexibility positions it favorably in such personalized regimens. Predictive biomarkers may optimize treatment efficacy, bolstering adoption.

Healthcare Policy and Cost Management

Healthcare systems prioritize cost containment. Demonstrating long-term cost savings through reduced hospitalizations and bleeding complications is pivotal. VONVENDI’s value proposition will increasingly hinge on real-world evidence supporting economic benefits.

Strategic Outlook and Investment Considerations

VONVENDI's positioning as a recombinant, pathogen-safe treatment aligns with evolving clinical preferences and safety standards. Its financial potential hinges on expanding indications, geographic reach, and demonstrating cost-effectiveness. Strategic partnerships with payers, clinicians, and patient advocacy groups will be instrumental.

However, competitive pressures from biosimilars and disruptive gene therapies pose significant threats. Companies must invest in R&D, patient education, and market access strategies to sustain long-term growth.

Key Takeaways

• Growing Demand: Rising diagnosis rates and expanding treatment guidelines underpin increasing utilization of VONVENDI, especially as recombinant products gain favor for safety reasons.

• Regulatory and Reimbursement Support: Favorable approvals and reimbursement landscapes facilitate market penetration, though cost considerations remain critical.

• Competitive Landscape: Intense competition from plasma-derived products, biosimilars, and forthcoming gene therapies necessitates differentiation through efficacy, safety, and economic value.

• Innovation Trajectory: Formulation improvements, personalized treatment approaches, and real-world evidence will shape VONVENDI’s market success over the next decade.

• Market Disruption Risks: Emergent curative options like gene therapy could significantly truncate the demand for biologic replacement therapies.

FAQs

1. What distinguishes VONVENDI from other treatments for von Willebrand disease?
VONVENDI is a recombinant, non-viral biologic that offers a pathogen-safe, standardized alternative to plasma-derived products, with a potentially favorable safety and immunogenicity profile. Its specific formulation targets both von Willebrand factor and factor VIII, providing tailored therapy.

2. How is VONVENDI positioned in comparison to gene therapy options?
Currently, VONVENDI serves as a reliable, approved biologic therapy with established safety. Gene therapies are still in experimental or early approval stages, aiming for potentially curative outcomes. VONVENDI remains essential for patients not eligible for gene therapy or while such innovative treatments mature.

3. What are the primary factors driving VONVENDI’s revenue growth?
Key drivers include increased diagnosis rates, broader clinical adoption, expanded geographic markets, and insurance coverage. Additionally, innovations improving dosing convenience and safety profiles will influence growth trajectories.

4. What barriers could impede VONVENDI’s market expansion?
Price sensitivity, competition from biosimilars, reimbursement complexities, and orients towards alternative curative treatments may limit uptake. Regulatory delays or unfavorable reimbursement policies could also pose challenges.

5. How might healthcare policy changes impact VONVENDI’s market?
Policy shifts favoring cost-effective, safety-enhanced therapies and incentivizing innovation can promote VONVENDI’s adoption. Conversely, emphasis on biosimilar competition and strict reimbursement criteria could constrain growth.

---

References
[1] World Federation of Hemophilia. "Global Hemophilia Overview." 2022.
[2] U.S. Food and Drug Administration. "VONVENDI Approval Notice." 2014.
[3] MarketsandMarkets. "Bleeding Disorder Therapeutics Market," 2022.
[4] EMA. "VONVENDI Summary of Product Characteristics." 2015.
[5] Noman et al., "Emerging Gene Therapies for Bleeding Disorders," Hematology Reports, 2021.
[6] EvaluatePharma. "Biologic Drugs Market Forecast," 2023.
[7] Parkin et al., "Gene Therapy in Hemophilia and VWD," Blood Advances, 2021.